{"id":7200,"date":"2019-03-18T17:25:18","date_gmt":"2019-03-19T00:25:18","guid":{"rendered":"https:\/\/www.bluerocktx.com\/?p=7200"},"modified":"2023-06-26T14:34:13","modified_gmt":"2023-06-26T18:34:13","slug":"bluerock-therapeutics-appoints-joachim-fruebis-ph-d-as-chief-development-officer","status":"publish","type":"post","link":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-appoints-joachim-fruebis-ph-d-as-chief-development-officer\/","title":{"rendered":"BlueRock Therapeutics Appoints Joachim Fruebis, Ph.D., as Chief Development Officer"},"content":{"rendered":"<ul>\n<li><strong>Strengthens executive team with drug development expertise to translate novel Cell+Gene platform into therapeutic programs<\/strong><\/li>\n<\/ul>\n<p><strong>CAMBRIDGE, Mass., March 18, 2019<\/strong>\u00a0\u2013 BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced the appointment of Joachim Fruebis, Ph.D., as Chief Development Officer. Dr. Fruebis will lead BlueRock\u2019s drug development efforts, including clinical and regulatory strategy, and will be responsible for driving BlueRock\u2019s novel programs across neurology, cardiology and autoimmune diseases through clinical development and toward regulatory approval. He will join BlueRock\u2019s executive team, reporting to Emile Nuwaysir, Chief Executive Officer of BlueRock.<\/p>\n<p>\u201cJoachim brings over two decades of industry experience with significant expertise leading global teams to successfully translate preclinical drug development candidates through clinical development, regulatory approval and commercialization,\u201d said Emile Nuwaysir, Ph.D., Chief Executive Officer of BlueRock Therapeutics. \u201cHe joins our team at an exciting and pivotal time at BlueRock as we work to advance multiple Cell+Gene platform candidates into the clinic. Joachim\u2019s leadership, clinical and regulatory background and demonstrated track record in bringing therapies to patients are an important addition to our growing R&amp;D team and capabilities.\u201d<\/p>\n<p>\u201cI am thrilled to be joining the BlueRock team as we work to drive transformative treatment options across neurological, cardiac and autoimmune disorders,\u201d said Joachim Fruebis, Ph.D., Chief Development Officer of BlueRock. \u201cI look forward to working with the executive team and our collaborators in leveraging our innovative Cell+Gene platform and advancing potentially life-altering medicines that could address multiple unmet medical needs.\u201d<\/p>\n<p>Dr. Fruebis brings more than 25 years of experience in the biopharmaceutical industry. He was most recently Senior Vice President, Clinical Development at Bioverativ (acquired by Sanofi). In this role, Dr. Fruebis was responsible for developing Bioverativ\u2019s rare disease program portfolio. Prior to Bioverativ, Dr. Fruebis served as Vice President, Senior Global Program Head for multiple disease areas, including hematology and ophthalmology at Bayer, a role in which he led cross-functional global teams responsible for the late-stage clinical development and commercialization of multiple products including the franchises for Eylea\u00ae, Kovaltry\u00ae and Jivi\u00ae. Prior to Bayer, Dr. Fruebis served as Vice President, External R&amp;D Innovation at Pfizer, a role in which he was responsible for the rare disease, ophthalmology and cardiovascular\/metabolic therapeutic areas. Dr. Fruebis received his Ph.D. and M.S. in Biology from the University Kaiserslautern, Germany for work conducted at UC San Diego, Dept of Medicine.<\/p>\n<p><strong>About BlueRock Therapeutics<\/strong><\/p>\n<p>BlueRock Therapeutics is an engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock\u2019s Cell+Gene platform harnesses the power of cells for new medicines across neurology, cardiology and autoimmune indications. BlueRock\u2019s cell differentiation technology recapitulates the cell\u2019s developmental biology to produce native cell therapies which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. BlueRock was founded in 2016 by Versant Ventures and capitalized with one of the largest-ever Series A financings in biotech history by Bayer AG and Versant. BlueRock\u2019s culture is defined by scientific innovation, highest ethical standards and an urgency to bring transformative treatments to all who would benefit. For more information, visit <a href=\"http:\/\/www.bluerocktx.com\">www.bluerocktx.com<\/a>.<\/p>\n<p>###<\/p>\n<p><strong>Investors:<\/strong><\/p>\n<p>Candice Ellis, 978-879-7273<br \/>\nAssociate Director, Investor Relations and Corporate Communications<br \/>\n<a href=\"mailto:cellis@bluerocktx.com\">cellis@bluerocktx.com<\/a><\/p>\n<p><strong>Media Contacts:<\/strong><br \/>\nDavid Schull or Maggie Beller Russo Partners, LLC<br \/>\n(646) 942-5631<br \/>\n<a href=\"mailto:Maggie.beller@russopartnersllc.com\">Maggie.beller@russopartnersllc.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Strengthens executive team with drug development expertise to translate novel Cell+Gene platform into therapeutic programs CAMBRIDGE, Mass., March 18, 2019\u00a0\u2013 BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced the appointment [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":7708,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[45],"tags":[54],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BlueRock Therapeutics Appoints Joachim Fruebis, Ph.D., as Chief Development Officer - BlueRock Therapeutics LP<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-appoints-joachim-fruebis-ph-d-as-chief-development-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BlueRock Therapeutics Appoints Joachim Fruebis, Ph.D., as Chief Development Officer - BlueRock Therapeutics LP\" \/>\n<meta property=\"og:description\" content=\"Strengthens executive team with drug development expertise to translate novel Cell+Gene platform into therapeutic programs CAMBRIDGE, Mass., March 18, 2019\u00a0\u2013 BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced the appointment [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-appoints-joachim-fruebis-ph-d-as-chief-development-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"BlueRock Therapeutics LP\" \/>\n<meta property=\"article:published_time\" content=\"2019-03-19T00:25:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-26T18:34:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/BR-Logo-Card.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"1000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"BlueRock Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"BlueRock Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-appoints-joachim-fruebis-ph-d-as-chief-development-officer\/\",\"url\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-appoints-joachim-fruebis-ph-d-as-chief-development-officer\/\",\"name\":\"BlueRock Therapeutics Appoints Joachim Fruebis, Ph.D., as Chief Development Officer - BlueRock Therapeutics LP\",\"isPartOf\":{\"@id\":\"https:\/\/www.bluerocktx.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-appoints-joachim-fruebis-ph-d-as-chief-development-officer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-appoints-joachim-fruebis-ph-d-as-chief-development-officer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/BR-Logo-Card.jpg\",\"datePublished\":\"2019-03-19T00:25:18+00:00\",\"dateModified\":\"2023-06-26T18:34:13+00:00\",\"author\":{\"@id\":\"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-appoints-joachim-fruebis-ph-d-as-chief-development-officer\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-appoints-joachim-fruebis-ph-d-as-chief-development-officer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-appoints-joachim-fruebis-ph-d-as-chief-development-officer\/#primaryimage\",\"url\":\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/BR-Logo-Card.jpg\",\"contentUrl\":\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/BR-Logo-Card.jpg\",\"width\":900,\"height\":1000,\"caption\":\"BlueRock Therapeutics Logo Card\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-appoints-joachim-fruebis-ph-d-as-chief-development-officer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.bluerocktx.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BlueRock Therapeutics Appoints Joachim Fruebis, Ph.D., as Chief Development Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.bluerocktx.com\/#website\",\"url\":\"https:\/\/www.bluerocktx.com\/\",\"name\":\"BlueRock Therapeutics LP\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.bluerocktx.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057\",\"name\":\"BlueRock Therapeutics\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.bluerocktx.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g\",\"caption\":\"BlueRock Therapeutics\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BlueRock Therapeutics Appoints Joachim Fruebis, Ph.D., as Chief Development Officer - BlueRock Therapeutics LP","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-appoints-joachim-fruebis-ph-d-as-chief-development-officer\/","og_locale":"en_US","og_type":"article","og_title":"BlueRock Therapeutics Appoints Joachim Fruebis, Ph.D., as Chief Development Officer - BlueRock Therapeutics LP","og_description":"Strengthens executive team with drug development expertise to translate novel Cell+Gene platform into therapeutic programs CAMBRIDGE, Mass., March 18, 2019\u00a0\u2013 BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced the appointment [&hellip;]","og_url":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-appoints-joachim-fruebis-ph-d-as-chief-development-officer\/","og_site_name":"BlueRock Therapeutics LP","article_published_time":"2019-03-19T00:25:18+00:00","article_modified_time":"2023-06-26T18:34:13+00:00","og_image":[{"width":900,"height":1000,"url":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/BR-Logo-Card.jpg","type":"image\/jpeg"}],"author":"BlueRock Therapeutics","twitter_card":"summary_large_image","twitter_misc":{"Written by":"BlueRock Therapeutics","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-appoints-joachim-fruebis-ph-d-as-chief-development-officer\/","url":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-appoints-joachim-fruebis-ph-d-as-chief-development-officer\/","name":"BlueRock Therapeutics Appoints Joachim Fruebis, Ph.D., as Chief Development Officer - BlueRock Therapeutics LP","isPartOf":{"@id":"https:\/\/www.bluerocktx.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-appoints-joachim-fruebis-ph-d-as-chief-development-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-appoints-joachim-fruebis-ph-d-as-chief-development-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/BR-Logo-Card.jpg","datePublished":"2019-03-19T00:25:18+00:00","dateModified":"2023-06-26T18:34:13+00:00","author":{"@id":"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057"},"breadcrumb":{"@id":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-appoints-joachim-fruebis-ph-d-as-chief-development-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.bluerocktx.com\/bluerock-therapeutics-appoints-joachim-fruebis-ph-d-as-chief-development-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-appoints-joachim-fruebis-ph-d-as-chief-development-officer\/#primaryimage","url":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/BR-Logo-Card.jpg","contentUrl":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/BR-Logo-Card.jpg","width":900,"height":1000,"caption":"BlueRock Therapeutics Logo Card"},{"@type":"BreadcrumbList","@id":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-appoints-joachim-fruebis-ph-d-as-chief-development-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.bluerocktx.com\/"},{"@type":"ListItem","position":2,"name":"BlueRock Therapeutics Appoints Joachim Fruebis, Ph.D., as Chief Development Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.bluerocktx.com\/#website","url":"https:\/\/www.bluerocktx.com\/","name":"BlueRock Therapeutics LP","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.bluerocktx.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057","name":"BlueRock Therapeutics","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.bluerocktx.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g","caption":"BlueRock Therapeutics"}}]}},"_links":{"self":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts\/7200"}],"collection":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/comments?post=7200"}],"version-history":[{"count":3,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts\/7200\/revisions"}],"predecessor-version":[{"id":7645,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts\/7200\/revisions\/7645"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/media\/7708"}],"wp:attachment":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/media?parent=7200"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/categories?post=7200"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/tags?post=7200"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}